Full Title
A Phase 1, First-in-human Study of JNJ-80948543, a T-cell Redirecting Antibody, in Participants with NHL and CLLPurpose
The purpose of this study is to find the highest dose of JNJ-80948543 immunotherapy that can be given safely in people with non-Hodgkin lymphoma (NHL) or chronic lymphocytic leukemia (CLL) that has come back or continued to grow despite prior treatment.
JNJ-80948543 is designed to help immune cells find and kill cancer cells. It binds to NHL and CLL cells and to T cells, which play a role in the immune response. JNJ-80948543 activates T cells and brings them closer to tumor cells to increase the chance of killing them. It is given as an injection under the skin.
Who Can Join
To be eligible for this study, patients must meet several requirements, including:
- Participants must have NHL or CLL that has come back or continued to grow despite treatment and cannot be successfully treated with existing therapies.
- At least 2 weeks must pass between the completion of previous therapies and receipt of JNJ-80948543.
- Patients must be physically well enough that they are able to be mobile, take care of themselves, and engage in all but physically strenuous activities. For example, they must be well enough that they could carry out office work or light housework.
- This study is for people age 18 and older.
Contact
For more information and to ask about eligibility for this study, please contact the office of Dr. Gilles Salles at 646-608-4153.